Investigational Drug Information for Prexasertib
✉ Email this page to a colleague
What is the development status for investigational drug Prexasertib?
Prexasertib is an investigational drug.
There have been 18 clinical trials for Prexasertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2018.
The most common disease conditions in clinical trials are Neoplasms, Neoplasm Metastasis, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).
There are three US patents protecting this investigational drug and seventy international patents.
Summary for Prexasertib
| US Patents | 3 |
| International Patents | 70 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2018-04-10) |
| Vendors | 41 |
Recent Clinical Trials for Prexasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | GOG Foundation | Phase 1/Phase 2 |
| A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | Acrivon Therapeutics | Phase 1/Phase 2 |
| A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | Memorial Sloan Kettering Cancer Center | Phase 1/Phase 2 |
Clinical Trial Summary for Prexasertib
Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib
US Patents for Prexasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Prexasertib | ⤷ Try a Trial | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate | Eli Lilly and Company (Indianapolis, IN) | ⤷ Try a Trial |
| Prexasertib | ⤷ Try a Trial | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) | ⤷ Try a Trial |
| Prexasertib | ⤷ Try a Trial | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | Eli Lilly and Company (Indianapolis, IN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Prexasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Prexasertib | Argentina | AR106772 | 2035-12-07 | ⤷ Try a Trial |
| Prexasertib | Australia | AU2016367041 | 2035-12-07 | ⤷ Try a Trial |
| Prexasertib | Brazil | BR112018008398 | 2035-12-07 | ⤷ Try a Trial |
| Prexasertib | Canada | CA3003914 | 2035-12-07 | ⤷ Try a Trial |
| Prexasertib | Chile | CL2018001432 | 2035-12-07 | ⤷ Try a Trial |
| Prexasertib | China | CN108349948 | 2035-12-07 | ⤷ Try a Trial |
| Prexasertib | Colombia | CO2018005676 | 2035-12-07 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
